ダルベポエチンアルファ（アラネスプ）の世界市場レポート 2025年

ダルベポエチンアルファ（アラネスプ）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.3％で75億1,000万米ドルに成長します。予測期間の成長は、ヘルスケア償還政策、認知度向上と教育、ヘルスケアインフラ開発、腎ケア需要、高齢化などに起因すると考えられます。予測期間の主な動向には、世界市場への浸透、デジタルヘルス統合、個別化治療アプローチ、バイオシミラーの採用、長時間作用型製剤などがあります。

慢性疾患の有病率の上昇は、今後のダルベポエチンアルファ市場の成長を牽引すると予想されます。慢性疾患とは、3カ月以上続き、時間の経過とともに悪化する病気のことです。ダルベポエチンアルファは、さまざまな慢性疾患の治療や、がん患者の化学療法による貧血を回復させるために使用されます。例えば、2024年6月、オーストラリア政府の法定機関であるオーストラリア保健福祉研究所は、2022年の慢性疾患による死亡者数は171,500人で、全死亡者数の90％を占め、人口10万人当たりの死亡率は659人であったと報告しました。慢性疾患による年齢標準化死亡率は、2020年には10万人当たり448人に減少したが、2021年には459人、2022年には490人に増加しました。したがって、慢性疾患の有病率の増加がダルベポエチンアルファ市場の成長を牽引しています。

糖尿病有病率の上昇は、今後ダルベポエチンアルファ市場の成長を促進すると予想されます。糖尿病とは、血糖値が高くなる長期的な代謝性疾患を指します。この疾患は、長期にわたって心臓、血管、目、腎臓、神経、その他の臓器に大きな害を及ぼします。ダルベポエチンアルファは、この疾患に伴う貧血に対処し、赤血球産生を促進し、全体的なQOLを改善することによって、糖尿病患者にとって重要な役割を果たしています。例えば、ベルギーに本部を置く国際糖尿病連合（IDF）によると、2022年6月、糖尿病の有病率は世界で10.5％に増加し、半数以上（44.7％）の人々がまだ診断を受けていないです。IDFの予測によると、2045年までに7億8,300万人の成人、つまり8人に1人が糖尿病になるといいます。これは46％の増加であり、同時期の人口増加予測（20％）の2倍以上です。したがって、糖尿病有病率の上昇がダルベポエチンアルファ市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のダルベポエチンアルファ（アラネスプ） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のダルベポエチンアルファ（アラネスプ）市場：成長率分析
• 世界のダルベポエチンアルファ（アラネスプ）市場の実績：規模と成長, 2019-2024
• 世界のダルベポエチンアルファ（アラネスプ）市場の予測：規模と成長, 2024-2029, 2034F
• 世界のダルベポエチンアルファ（アラネスプ）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のダルベポエチンアルファ（アラネスプ）市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• エポゲン
• プロクリット
• アラネスプ
• その他のタイプ
• 世界のダルベポエチンアルファ（アラネスプ）市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のダルベポエチンアルファ（アラネスプ）市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 慢性腎臓病患者
• がん患者
• その他の用途
• 世界のダルベポエチンアルファ（アラネスプ）市場、タイプ別サブセグメンテーション：エポジェン、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標準処方
• 強化処方
• 世界のダルベポエチンアルファ（アラネスプ）市場、タイプ別サブセグメンテーション：プロクリット、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標準処方
• バイオシミラー
• 世界のダルベポエチンアルファ（アラネスプ）市場、タイプ別サブセグメンテーション：アラネスプ、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単回投与バイアル
• マルチドーズバイアル
• 世界のダルベポエチンアルファ（アラネスプ）市場、タイプ別サブセグメンテーション：その他、実績と予測, 2019-2024, 2024-2029F, 2034F
• 併用療法
• 代替赤血球生成刺激剤

第7章 地域別・国別分析

• 世界のダルベポエチンアルファ（アラネスプ）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のダルベポエチンアルファ（アラネスプ）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ダルベポエチンアルファ（アラネスプ）市場：競合情勢
• ダルベポエチンアルファ（アラネスプ）市場：企業プロファイル
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Mylan N.V. Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Serum Institute of India Pvt. Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Dr. Reddy's Laboratories Ltd.
• Cipla Ltd.
• Biocon Ltd.
• Reliance Life Sciences
• Torrent Pharmaceuticals Ltd.
• 3SBio Inc.
• Cadila Healthcare Ltd.
• Dong-A ST Co. Ltd.
• Chong Kun Dang Holdings
• Hetero Drugs Ltd.
• Intas Pharmaceuticals Ltd.
• Avesthagen Pharma
• Stada Arzneimittel AG
• Ranbaxy Laboratories Ltd.
• Sandoz International GmbH

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ダルベポエチンアルファ（アラネスプ）市場2029：新たな機会を提供する国
• ダルベポエチンアルファ（アラネスプ）市場2029：新たな機会を提供するセグメント
• ダルベポエチンアルファ（アラネスプ）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Darbepoetin alfa (Aranesp) is a medication utilized in treating anemia associated with chemotherapy and chronic kidney disease by stimulating the production of red blood cells in the bone marrow.

The primary variations of darbepoetin alfa (Aranesp) include Epogen, Procrit, Aranesp, and other related forms. Epogen is a synthetic protein designed to boost the body's red blood cell production and is specifically employed to address anemia, characterized by a deficiency of red blood cells. These medications are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and find application in treating patients with chronic kidney disease, individuals with cancer, and other relevant medical conditions.

The darbepoetin alfa market research report is one of a series of new reports from The Business Research Company that provides darbepoetin alfa market statistics, including darbepoetin alfa industry global market size, regional shares, competitors with darbepoetin alfa market share, detailed darbepoetin alfa market segments, market trends, and opportunities, and any further data you may need to thrive in the darbepoetin alfa industry. This darbepoetin alfa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The darbepoetin alfa (aranesp) market size has grown strongly in recent years. It will grow from $5.81 billion in 2024 to $6.11 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to anemia treatment advancements, erythropoiesis-stimulating agents (ESAs) demand, biopharmaceutical innovation, clinical acceptance, and improved patient outcomes

The darbepoetin alfa (aranesp) market size is expected to see strong growth in the next few years. It will grow to $7.51 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to healthcare reimbursement policies, increased awareness and education, healthcare infrastructure development, renal care demands, aging population. Major trends in the forecast period include global market penetration, digital health integration, personalized treatment approaches, adoption of biosimilars, and long-acting formulations.

The rising prevalence of chronic diseases is expected to drive the growth of the darbepoetin alfa market in the future. A chronic disease is an illness that lasts three months or longer and can worsen over time. Darbepoetin alfa is used to treat various chronic diseases and to reverse chemotherapy-induced anemia in cancer patients. For instance, in June 2024, the Australian Institute of Health and Welfare, a statutory authority of the Australian Government, reported that chronic conditions were responsible for 171,500 deaths in 2022, accounting for 90% of all deaths, with a rate of 659 per 100,000 population. The age-standardized death rate due to chronic conditions decreased to 448 per 100,000 in 2020 but rose to 459 in 2021 and 490 in 2022. Therefore, the increasing prevalence of chronic diseases is driving the growth of the darbepoetin alfa market.

The rising prevalence of diabetes is expected to propel the growth of the darbepoetin alfa market going forward. Diabetes refers to a long-term metabolic disease that causes high blood glucose levels. Over time, this condition causes major harm to the heart, blood vessels, eyes, kidneys, nerves, and other organs. Darbepoetin alfa plays a crucial role in diabetes patients by addressing the anemia associated with the condition, promoting red blood cell production, and improving overall quality of life. For instance, in June 2022, according to the International Diabetes Federation, a Belgium-based diabetes federation, the prevalence of diabetes had increased to 10.5% worldwide, with over half (44.7%) of people still undiagnosed. According to IDF predictions, 783 million adults, or one in eight people, will have diabetes by 2045. This would represent a 46% rise, more than double the projected population growth for the same period (20%). Therefore, the rising prevalence of diabetes is driving the growth of the darbepoetin alfa market.

Product innovation stands out as a significant trend gaining momentum in the darbepoetin alfa market, with major companies strategically adopting new technologies to secure their market positions. GlaxoSmithKline Ltd., a UK-based pharmaceutical and biotechnology company, exemplifies this trend by introducing Jesduvroq (daprodustat) in February 2023. The US Food and Drug Administration (FDA), a US-based government agency, approved Jesduvroq as an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the once-daily treatment of anemia induced by chronic kidney disease (CKD) in individuals on dialysis for at least four months.

Major companies in the darbepoetin alfa market are intensifying their focus on introducing novel medications to gain a competitive advantage. A case in point is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to address anemia associated with chronic kidney disease. Akebia Therapeutics, a US-based biotechnology company, obtained approval from Australia's Therapeutic Goods Administration (TGA) for Vafseo in September 2023. This approval extends to 36 countries, including Taiwan, and is based on the positive outcomes from the global Phase 3 clinical program demonstrating the efficacy of vadadustat in treating anemia due to CKD in adults on chronic maintenance dialysis. The commitment to introducing innovative products reflects the dedication of major companies in advancing solutions within the darbepoetin alfa market.

In November 2022, Biocon Biologics Ltd., an India-based biopharmaceutical company, acquired Viatris Inc. for an undisclosed amount. This acquisition equips Biocon Biologics with direct commercial capabilities and supporting infrastructure in advanced markets and several emerging markets, bringing it closer to patients, customers, and payors. Viatris Inc. is a U.S.-based provider of darbepoetin alfa.

Major companies operating in the darbepoetin alfa (aranesp) market include Johnson & Johnson, Amgen Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Serum Institute of India Pvt. Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Biocon Ltd., Reliance Life Sciences, Torrent Pharmaceuticals Ltd., 3SBio Inc., Cadila Healthcare Ltd., Dong-A ST Co. Ltd., Chong Kun Dang Holdings, Hetero Drugs Ltd., Intas Pharmaceuticals Ltd., Avesthagen Pharma, Stada Arzneimittel AG, Ranbaxy Laboratories Ltd., Sandoz International GmbH, Shandong Kexing Bioproducts Co. Ltd., Kyowa Kirin Co. Ltd., Polifarma S.p.A.

North America was the largest region in the darbepoetin alfa market in 2024. The regions covered in the darbepoetin alfa (aranesp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the darbepoetin alfa (aranesp) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The darbepoetin alfa market consists of sales of Aranesp sure click, Aranesp albumin free, and Aranesp sing eject. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Darbepoetin Alfa (Aranesp) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on darbepoetin alfa (aranesp) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for darbepoetin alfa (aranesp) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The darbepoetin alfa (aranesp) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Epogen; Procrit; Aranesp; Other Types
• 2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 3) By Application: Patients With Chronic Kidney Disease; Patients With Cancer; Other Applications
• Subsegments:
• 1) By Epogen: Standard Formulations; Enhanced Formulations
• 2) By Procrit: Standard Formulations; Biosimilars
• 3) By Aranesp: Single-Dose Vials; Multi-Dose Vials
• 4) By Other Types: Combination Therapies; Alternative Erythropoiesis-Stimulating Agents
• Companies Mentioned: Johnson & Johnson; Amgen Inc.; Mylan N.V.; Teva Pharmaceutical Industries Ltd.; Serum Institute of India Pvt. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Darbepoetin Alfa (Aranesp) Market Characteristics

3. Darbepoetin Alfa (Aranesp) Market Trends And Strategies

4. Darbepoetin Alfa (Aranesp) Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Darbepoetin Alfa (Aranesp) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Darbepoetin Alfa (Aranesp) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Darbepoetin Alfa (Aranesp) Market Growth Rate Analysis
• 5.4. Global Darbepoetin Alfa (Aranesp) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Darbepoetin Alfa (Aranesp) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Darbepoetin Alfa (Aranesp) Total Addressable Market (TAM)

6. Darbepoetin Alfa (Aranesp) Market Segmentation

• 6.1. Global Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epogen
• Procrit
• Aranesp
• Other Types
• 6.2. Global Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.3. Global Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Patients With Chronic Kidney Disease
• Patients With Cancer
• Other Applications
• 6.4. Global Darbepoetin Alfa (Aranesp) Market, Sub-Segmentation Of Epogen, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard Formulations
• Enhanced Formulations
• 6.5. Global Darbepoetin Alfa (Aranesp) Market, Sub-Segmentation Of Procrit, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard Formulations
• Biosimilars
• 6.6. Global Darbepoetin Alfa (Aranesp) Market, Sub-Segmentation Of Aranesp, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Dose Vials
• Multi-Dose Vials
• 6.7. Global Darbepoetin Alfa (Aranesp) Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Combination Therapies
• Alternative Erythropoiesis-Stimulating Agents

7. Darbepoetin Alfa (Aranesp) Market Regional And Country Analysis

• 7.1. Global Darbepoetin Alfa (Aranesp) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Darbepoetin Alfa (Aranesp) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Darbepoetin Alfa (Aranesp) Market

• 8.1. Asia-Pacific Darbepoetin Alfa (Aranesp) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Darbepoetin Alfa (Aranesp) Market

• 9.1. China Darbepoetin Alfa (Aranesp) Market Overview
• 9.2. China Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Darbepoetin Alfa (Aranesp) Market

• 10.1. India Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Darbepoetin Alfa (Aranesp) Market

• 11.1. Japan Darbepoetin Alfa (Aranesp) Market Overview
• 11.2. Japan Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Darbepoetin Alfa (Aranesp) Market

• 12.1. Australia Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Darbepoetin Alfa (Aranesp) Market

• 13.1. Indonesia Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Darbepoetin Alfa (Aranesp) Market

• 14.1. South Korea Darbepoetin Alfa (Aranesp) Market Overview
• 14.2. South Korea Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Darbepoetin Alfa (Aranesp) Market

• 15.1. Western Europe Darbepoetin Alfa (Aranesp) Market Overview
• 15.2. Western Europe Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Darbepoetin Alfa (Aranesp) Market

• 16.1. UK Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Darbepoetin Alfa (Aranesp) Market

• 17.1. Germany Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Darbepoetin Alfa (Aranesp) Market

• 18.1. France Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Darbepoetin Alfa (Aranesp) Market

• 19.1. Italy Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Darbepoetin Alfa (Aranesp) Market

• 20.1. Spain Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Darbepoetin Alfa (Aranesp) Market

• 21.1. Eastern Europe Darbepoetin Alfa (Aranesp) Market Overview
• 21.2. Eastern Europe Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Darbepoetin Alfa (Aranesp) Market

• 22.1. Russia Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Darbepoetin Alfa (Aranesp) Market

• 23.1. North America Darbepoetin Alfa (Aranesp) Market Overview
• 23.2. North America Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Darbepoetin Alfa (Aranesp) Market

• 24.1. USA Darbepoetin Alfa (Aranesp) Market Overview
• 24.2. USA Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Darbepoetin Alfa (Aranesp) Market

• 25.1. Canada Darbepoetin Alfa (Aranesp) Market Overview
• 25.2. Canada Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Darbepoetin Alfa (Aranesp) Market

• 26.1. South America Darbepoetin Alfa (Aranesp) Market Overview
• 26.2. South America Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Darbepoetin Alfa (Aranesp) Market

• 27.1. Brazil Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Darbepoetin Alfa (Aranesp) Market

• 28.1. Middle East Darbepoetin Alfa (Aranesp) Market Overview
• 28.2. Middle East Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Darbepoetin Alfa (Aranesp) Market

• 29.1. Africa Darbepoetin Alfa (Aranesp) Market Overview
• 29.2. Africa Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Darbepoetin Alfa (Aranesp) Market Competitive Landscape And Company Profiles

• 30.1. Darbepoetin Alfa (Aranesp) Market Competitive Landscape
• 30.2. Darbepoetin Alfa (Aranesp) Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Mylan N.V. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Serum Institute of India Pvt. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Darbepoetin Alfa (Aranesp) Market Other Major And Innovative Companies

• 31.1. Dr. Reddy's Laboratories Ltd.
• 31.2. Cipla Ltd.
• 31.3. Biocon Ltd.
• 31.4. Reliance Life Sciences
• 31.5. Torrent Pharmaceuticals Ltd.
• 31.6. 3SBio Inc.
• 31.7. Cadila Healthcare Ltd.
• 31.8. Dong-A ST Co. Ltd.
• 31.9. Chong Kun Dang Holdings
• 31.10. Hetero Drugs Ltd.
• 31.11. Intas Pharmaceuticals Ltd.
• 31.12. Avesthagen Pharma
• 31.13. Stada Arzneimittel AG
• 31.14. Ranbaxy Laboratories Ltd.
• 31.15. Sandoz International GmbH

32. Global Darbepoetin Alfa (Aranesp) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Darbepoetin Alfa (Aranesp) Market

34. Recent Developments In The Darbepoetin Alfa (Aranesp) Market

35. Darbepoetin Alfa (Aranesp) Market High Potential Countries, Segments and Strategies

• 35.1 Darbepoetin Alfa (Aranesp) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Darbepoetin Alfa (Aranesp) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Darbepoetin Alfa (Aranesp) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer